StudyFinder

Search Results Within Category "Skin Conditions"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
16 Study Matches

A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of Higher Doses of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure

Phase 1, Double- Blind Study, 15 week study, Patch test and Vaccine Injection, Males/Females 18-65 years old with history of urushiol exposure. The rash or allergic contact dermatitis of poison ivy is recognized as occurring after the exposure to the urushiol oil which is found in the leaves of poison ivy, oak and sumac. Currently there is no preventative treatment for contact dermatitis. The purpose of this study is to find out if the vaccine, PDC-APB can help with the prevention of contact dermatitis.

Yes
 

James Marks
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014416
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Documented history of Poison Ivy (urushiol) exposure with a rash
Willing to follow all study instructions
Attend all study visits

Exclusion Criteria:
use of certain medications not allowed; study coordinator will provide more information
Positive test result of HIV, Hepatitis B or Hepatitis C
Participation in an investigational drug or device study within 30 days prior to screening
There are over the counter medications that are not permitted during the study participation, the study coordinator will discuss the list during the screening process.
Skin Conditions
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Content Validation of PROMIS 8a and the Development of an Instrument to Measure Drainage in Hidradenitis Suppurativa (HS)

The purpose of this study is to investigate the use and effectiveness of fatigue and drainage measurement tools for patients with hidradenitis suppurativa (HS). Participants will complete either an interview through Zoom or an online questionnaire.

Participants in this study will either complete an interview through Zoom or an online questionnaire to talk about their experiences with hidradenitis suppurativa fatigue and drainage.

No
 

Joslyn Kirby
Tierney Wallace - at twallace3@pennstatehealth.psu.edu or 717-531-0003, ext=286790
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00022216
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with Hidradenitis Suppurativa (HS)
Experienced fatigue as a result of your HS
Fluent in English

Exclusion Criteria:
Not fluent in English
Skin Conditions
Not applicable
I'm interested
Share via email

A Multicenter, Open-Label, Single Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.

Participants will attend in person visit at the Dermatology Clinical Trial office. Dr. Zaenglein is the pediatric dermatologist in charge of this research study and will do all skin evaluations. In addition at different time points there will be blood that is drawn, questionnaires to be completed, and ECGs will be performed.

Study coordinator will discuss.

Yes
 

Andrea Zaenglein
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

Female
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT04921345
SITE00001016
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 2-11 years old
Diagnosed with Moderate to Severe Atopic Dermatitis
Willing to attend all study visits and follow directions

Exclusion Criteria:
Certain treatments for atopic dermatitis are not allowed; study coordinator will discuss
Had a documented asthma exacerbation requiring hospitalization in the past 12 months.
Weigh less than 22 pounds
Skin Conditions
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Defining the cellular and molecular signatures that are associated with the clinical heterogeneity of hidradenitis suppurativa

Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.

Eligible participants will attend a one time in person visit. During the visit, the study team will ask you to participate in the following activities: collect skin sample, blood sample and cheek swab. Take photographs of your HS lesions.

study coordinator will discuss.

Yes
 

Amanda Nelson
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-1513
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00012908
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years and older
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants

Exclusion Criteria:
Patients who are Pregnant
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed
Skin Conditions
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadaticinib in Pediatric Subjects with Severe Atopic Dermatitis

Phase 1, multiple-dose, open-label study consisting oftwo parts, male and female subjects aged 2 to 12 years with severe atopic dermatitis (eczema).

Yes
 

Andrea Zaenglein
Samantha Gettle - at sgettle2@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT03646604
SITE00000468
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
must weight 22 pounds or more
Have a diagnosis of Atopic Dermatitis for at least 6 months

Exclusion Criteria:
Certain treatments are not allowed; coordinator will discuss specific treatments
No active Hep A, Hep C or Hep B
Current participation in another clinical trial
Skin Conditions
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Reliability and Validity Testing of the Internalized Skin Bias Questionnaire – Revised

Studies have show that patients with skin conditions are often subject to social stigma. Exposure to these negative biases can lead to negative feelings for the patient. This study seeks to evaluate how patients with various skin conditions are impacted by these social biases.

Take an online survey that is expected to take 15-20 minutes. You will be asked to provide your email and take a short (5-10 minute) survey with some of the same questions 72 hours later.

No
 

Melissa Butt
Melissa Butt - at mab787@psu.edu
Public Health Sciences (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00022407
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult (18 or older)
Access to the internet
Must have a skin condition (Hidradenitis Suppurativa, Acne, Psoriasis, Atopic Dermatitis (Eczema), Vitiligo, Cutaneous lupus erythematosus, Rosacea, etc.)
Read/write in English

Exclusion Criteria:
Children (17 and under)
Those unable to consent
Those without a skin condition
Unable to read/write in English
Skin Conditions
Not applicable
I'm interested
Share via email

A randomized, double blind, vehicle-controlled, multicenter Phase II study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of moderate to severe Acne vulgaris in adults with photodynamic therapy (PDT)

Moderate to Severe Acne Vulgaris: Males/Females 16 years and older. You will receive the study drug with either 1 hour or 3 hours between study drug application and illumination. The purpose of this study is to test the effectiveness and safety of the study drug, used at two different incubation times (time starting with administration of study drug until start of the red light illumination).

Subjects will attend in person visits in the Dermatology Clinical Trial Office. Your length of participation will depend on how your acne responds to the first treatment; the length of participation for 3 treatments will be approximately 25 weeks.Throughout the study at different time points Dr. Zaenglein will evaluate your acne, blood will be drawn, photos will be taken, and questionnaires will need to be completed.

Study Coordinator will discuss during phone screen.

Yes
 

Andrea Zaenglein
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT05080764
SITE00001055
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 16 years and older may be eligible to participate.
willingness to stop topical facial treatments other than medical cleansers at least 14 days prior to receiving investigational product.
For females must use an adequate and highly effective or two effective methods of contraception throughout the study. Study coordinator will discuss.

Exclusion Criteria:
History of soy or peanut allergy.
For males- beard or other facial hair that might interfere with the study assessments unless subject agrees to be clean-shaven throughout the entire study period.
Certain medications/treatments not allowed during the study; study coordinator will discuss.
Skin Conditions
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER COMPARATIVE EFFECTIVENESS STUDY OF SPIRONOLACTONE VERSUS DOXYCYCLINE HYCLATE FOR THE TREATMENT OF ACNE IN WOMEN

Mild to Severe Acne: Women ages 16-40 years. Assigned to either spironolactone of doxycycline; oral medication taken once daily. The duration of the study will last 16 weeks. During that time participants will attend 3 in person study visits (study start, week 8 and week 16). In addition participants will completion questions outside of study visits at Week 4 and Week 12. The goal of this trial is to compare the effectiveness of spironolactone and doxycycline hyclate in the treatment of acne in women.

The duration of the study will last 16 weeks. During that time participants will attend 3 in person study visits (study start, week 8 and week 16). In addition participants will completion questions outside of study visits at Week 4 and Week 12.

Yes
 

Joslyn Kirby
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

Female
All
This study is NOT accepting healthy volunteers
NCT04582383
SITE00001097
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Assigned female at birth; ages 16-40 years old
Birth control options will be discussed by study coordinator

Exclusion Criteria:
Certain acne treatments are not allowed; study coordinator will discuss
Certain medical history conditions are not allowed; study coordinator will discuss
Skin Conditions
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Assessing the treatment of scalp conditions in adult patients

This study is aiming to identify the differences in medicated hair care practices amongst adult patients with scalp conditions. Typical treatment for scalp conditions involves the continued use of medicated shampoos; however, hair care practices across all ethnic and racial barriers are different. This could impact the effectiveness of these medicated washes if they are by chance not being used frequently enough. To our knowledge, no research has explored hair care practices and their relationship to dermatological conditions that affect the scalp.

Participants will complete a one-time survey that will take approximately 5-10 minutes.

No
 

Lauren Hollins
Tierney Wallace - at twallace3@pennstatehealth.psu.edu
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00015439
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over 18
Access to email and internet
Have sebhorreic dermatitis, sebopsoriasis, dandruff, or psoriasis of the scalp

Exclusion Criteria:
Any other skin conditions
Any scalp conditions with open wounds or sores
Skin Conditions
Survey(s)
I'm interested
Share via email

Assessing the impact of post-inflammatory hyperpigmentation on quality of life in people of color

This survey study is looking to see how post-inflammatory hyperpigmentation (PIH) affects quality of life in people with skin of color.

Participants will complete a one-time survey that will ask about post-inflammatory hyperpigmentation.

No
 

Lauren Hollins
Tierney Wallace - at twallace3@pennstatehealth.psu.edu or 717-531-6117
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00021979
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 18-89
Experienced/experiencing post-inflammatory hyperpigmentation

Exclusion Criteria:
Individuals with acanthosis nigricans
Individuals who are not able to understand English
Skin Conditions
Survey(s)
I'm interested
Share via email

Skin pathophysiology of Hidradenitis Suppurativa

The purpose of this research study is to collect skin samples from volunteers with HS and volunteers with healthy skin. The collected skin samples will be processed and compared to each other to see if there are specific differences in the skin between the HS volunteer group and the healthy skin volunteer group.

Participants will need to come to a one-time, in-person visit where biopsies (small skin samples) will be collected.- For participants with HS: Up to 4 biopsies will be collected - For participants with healthy skin: Up to 2 biopsies will be collected

Yes
 

Amanda Nelson
Samantha Gettle - at sgettle2@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00020589
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of hidradenitis suppurativa (HS)
HS lesions present in the armpits and/or groin

Exclusion Criteria:
Participants who are pregnant or are planning to become pregnant
Certain medications are not allowed in this study- the study team will provide details
Skin Conditions
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa

Male and female subjects with HS who are being considered to have surgery will be randomized to receive treatment of Humira or Placebo. There are three phases of the study during the 24 weeks.

Yes
 

Joslyn Kirby
Logan Claar - at lclaar@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02808975
SITE00000276
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be able to travel to Hershey Medical Center for 12 visits
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home

Exclusion Criteria:
Prior treatment of Humira or other biologics for the treatment of HS
Skin Conditions
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Exploratory Trial of Ruxolitinib 1.5% Cream for Early Stage Hidradenitis Suppurativa

Explore all stages of Hidradenitis Suppurativa with a topical medication.

There will be 7 in-person visits and 1 follow-up phone call over a 33 week period. Over the course of the study, the following study procedures will take place: medical history and medication history collection, ECG, lab tests (both blood and urine), photography, skin exams, physical exams, questionnaires, and skin biopsies.

Up to $350

Yes
 

Joslyn Kirby
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04414514
STUDY00016042
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must have diagnosis of HS for at least 3 months (90 days)
Must have active HS in at least 1 area
Must have negative TB screening assessment
Certain medications can be continued if on stable dose; study coordinator will discuss further.

Exclusion Criteria:
Any other active skin disease or condition that may interfere with assessment of HS
Pregnant (or considering becoming pregnant) or lactating females
Does not have reliable internet access for weekly electronic surveys
Skin Conditions
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Incidence Rates of Hair Loss in Women Who Wear Hijab

The aim of this study is to obtain information regarding the incidence of hair-related concerns in women who wear hijab and to collect information pertaining to factors that could contribute to hair loss in women who wear the hijab.

This survey study will involve a one-time survey that will take 5-10 minutes.

No
 

Matthew Helm
Tierney Wallace - at twallace3@pennstatehealth.psu.edu or 717-531-6117
Dermatology (HERSHEY)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023070
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Wear the hijab
Women
Read and understand English
Ages 18 years and older

Exclusion Criteria:
Do not meet inclusion criteria
Skin Conditions
Not applicable
I'm interested
Share via email

A Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa

This study is a placebo-controlled study testing the effectiveness and safety of a new drug (izokibep) in adults with hidradenitis suppurativa (HS). HS is a condition where painful skin lesions occur, most often in places on the body where there is friction (ex: armpits, under the breasts, buttocks, and groin). These lesions can drain and scar and will often reoccur.

For this study, participants will come to the study site about 17 times over approximately 59 weeks. During these visits, there will information about medical history and medications collected as well as demographic information, physical and skin exams, vital signs, blood and urine lab testing, ECGs, a chest x-ray, questionnaires, and a daily diary.

Yes
 

Joslyn Kirby
Dermatology Clinical Trials - at dermatologyclinicaltrials@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05905783
SITE00001430
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of HS for at least 6 months
HS in at least 2 body sites
Willingness to follow study rules and instructions of study staff

Exclusion Criteria:
History of active IBD
Chronic pain not associated with HS
History of HIV
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects

Phase 3, global, randomized, double-blind, placebo-controlled, multi-center study that will evaluate upadacitinib in the treatment of moderate to severe HS in adult and adolescent subjects who have failed to respond to or are intolerant of ant-TNF therapy and/or 1 approved non-anti-TNF-biologic therapy for HS.This study is comprised of a 35-day screening period, a 16 week placebo-controlled, double-blinded treatment period (Period 1), a 20-week re-randomized extension treatment period (Period 2), a 68-week long-term extension treatment period (Period 3) and a 30-day follow-up period.

You will completed 3 study periods over approximately 104 weeks. During that time at different time points you will have your skin examined, ECG, complete questionnaires, and have your labs drawn. In addition you will take the study medication as directed by the research study coordinators.

Yes
 

Joslyn Kirby
Dermatology Clinical Trials - at dermatologyclinicaltrial@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT05889182
SITE00001422
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
12 years of age and older
2 active HS areas
History of previous use ≥ 1 TNF inhibitor for at least 12 weeks and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks - study coordinator will discuss
Must agree to use daily wash

Exclusion Criteria:
Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; subjects with a history of gastric banding/segmentation are not excluded. - Study coordinator will discuss
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,